close
114th Congress: We're updating with new data as it becomes available.

H.R.4087 - Prescription Drug Labeling Promotion Act of 2012

To provide for the development and dissemination of best practices to ensure that visually-impaired and blind individuals in the United States have safe, consistent, reliable, and independent access to the information in prescription drug labeling. view all titles (2)

All Bill Titles

  • Official: To provide for the development and dissemination of best practices to ensure that visually-impaired and blind individuals in the United States have safe, consistent, reliable, and independent access to the information in prescription drug labeling. as introduced.
  • Short: Prescription Drug Labeling Promotion Act of 2012 as introduced.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.

Bill’s Views

  • Today: 3
  • Past Seven Days: 4
  • All-Time: 1,886
 
Introduced
 
House
Passes
 
Senate
Passes
 
President
Signs
 

 
02/24/12
 
 
 
 
 
 
 

Sponsor

M000133

Senator

Edward Markey

D-MA

View Co-Sponsors (10)

Official Summary

Prescription Drug Labeling Promotion Act of 2012 - Directs the Secretary of Health and Human Services (HHS) to establish a working group to develop best practices on access to prescription drug labeling for the visually impaired. Requires the working group to: (1) include equal representati

Official Summary

Prescription Drug Labeling Promotion Act of 2012 - Directs the Secretary of Health and Human Services (HHS) to establish a working group to develop best practices on access to prescription drug labeling for the visually impaired. Requires the working group to:
(1) include equal representation of consumer and industry advocates;
(2) promulgate guidance on best practices for pharmacies to ensure that blind and visually impaired individuals have safe, consistent, reliable, and independent access to the information in the labeling of prescription drugs;
(3) consider the use of Braille, specified auditory means, and enhanced visual means to provide such access; and
(4) consider whether there are technical, financial, manpower, or other factors that may fundamentally impact the ability of pharmacies with 20 or fewer retail locations to implement the best practices. Directs the Commissioner of Food and Drugs (FDA) to conduct an informational and educational program to inform the public and pharmacists about such guidance and practices. Directs the Comptroller General:
(1) 18 months after such guidance and practices are published, to review pharmacy compliance and the extent to which access barriers continue; and
(2) by September 30, 2016, to report on such review, including recommendations for reducing such barriers.

...Read the Rest




Vote on This Bill

100% Users Support Bill

1 in favor / 0 opposed
 

Send Your Rep a Letter

about this bill Support Oppose Tracking
Track with MyOC